Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
El Shatby University Hospital for Obstetrics and Gynecology
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06812559CT.gov Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome | — | Completed | — | — | — |
NCT04597099CT.gov Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion | — | Unknown | — | — | — |
NCT05112692CT.gov Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles | — | Unknown | — | — | — |
NCT05189873CT.gov GnRH Agonist Plus Hormone Replacement Therapy vs Hormone Replacement Therapy on IVF Outcomes | — | Completed | — | — | — |
NCT03068910CT.gov Hyperandrogenemia and Altered Day-night LH Pulse Patterns | — | Recruiting | — | — | — |
NCT05062135CT.gov Progesterone Action on Endometrium of PCOS | — | Completed | — | — | — |
NCT03088046CT.gov Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome | — | Completed | — | — | — |
NCT02352597CT.gov Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS | — | Completed | — | — | — |
NCT03440359CT.gov Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole | — | Completed | — | — | — |
NCT01428245CT.gov Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition | — | Terminated | — | — | — |
Show 7 more trialsShow fewer
NCT01428089CT.gov Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone | — | Unknown | — | — | — |
NCT01070160CT.gov Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS) | — | Completed | — | — | — |
NCT01427595CT.gov Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone | — | Completed | — | — | — |
NCT00805935CT.gov Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) | — | Completed | — | — | — |
NCT00805207CT.gov Sex Steroids, Sleep, and Metabolic Dysfunction in Women | — | Completed | — | — | — |
NCT01428193CT.gov Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone | — | Terminated | — | — | — |
NCT01425541CT.gov Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Polycystic Ovary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Progesterone (this asset) | El Shatby University Hospital for Obstetrics and Gynecology | Approved | BB · 71 |
| Human Chorionic Gonadotropin | Eman Basuni Ebrahim Mowad | P4 | BBB |
| Liraglutide | Peking University Third Hospital | P4 | BBB |
| Semaglutide | Methodist Health System | P4 | BBB |
| Drospirenone | Ege University | P4 | BBB |
| Follitropin Beta | Universitair Ziekenhuis Brussel | P4 | BBB |
| Ethinyl Estradiol | Ege University | P4 | BBB |
| Glucophage | Near East University, Turkey | P4 | BBB |
| Metformin | Beni-Suef University | P4 | BBB |
+41 more in the Polycystic Ovary Syndrome cohort
Other indications for Progesterone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Traumatic Brain Injury | — | P4 | BB · 67 |
| Infertility Disorder | — | P4 | BB · 66 |
| Osteoporosis | — | P4 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Progesterone in Polycystic Ovary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/progesterone-polycystic-ovary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →